Thalassemia Basics - Globin Chain Gang
- Quantitative defect in globin chain synthesis (α or β), leading to a microcytic, hypochromic anemia.
- The imbalance of chains causes ineffective erythropoiesis and hemolysis.
- Normal Adult Hemoglobins:
- HbA (Adult): $α_2β_2$ (~95-98%)
- HbA2 (Adult 2): $α_2δ_2$ (~2-3%)
- HbF (Fetal): $α_2γ_2$ (<2%)

⭐ Heterozygous thalassemia carriers show increased resistance to severe P. falciparum malaria.
Alpha-Thalassemia - Alpha's Missing Acts
- Pathophysiology: Caused by α-globin gene deletions on chromosome 16. Severity depends on the number of deleted genes (out of 4).
- cis deletion (prevalent in Asian populations) vs. trans deletion (prevalent in African populations).
- Clinical Spectrum:
- 1 deletion: Silent carrier, asymptomatic.
- 2 deletions: α-thalassemia trait with mild microcytic anemia.
- 3 deletions: HbH disease, where excess β-globin forms $β_4$ tetramers. Leads to severe hemolytic anemia & splenomegaly.
- 4 deletions: Hydrops fetalis (Hb Barts), where excess γ-globin forms $γ_4$ tetramers. It is lethal in utero.
⭐ In HbH disease, the precipitated $β_4$ tetramers (Heinz bodies) are visualized on supravital staining, giving RBCs a characteristic "golf ball" appearance.

Beta-Thalassemia - Beta's Bad Build
- Pathophysiology: Point mutations in the β-globin gene on chromosome 11 → ↓ or absent β-globin chain synthesis.
- Types:
- Minor (Trait): Heterozygous. Asymptomatic with mild microcytic anemia.
- Major (Cooley's Anemia): Homozygous. Severe, transfusion-dependent anemia.
- Clinical Features (Major):
- Ineffective erythropoiesis & extramedullary hematopoiesis → massive hepatosplenomegaly.
- Marrow expansion → "crew-cut" skull X-ray & "chipmunk" facies.
- Presents around 6 months as fetal hemoglobin (HbF) wanes.
- Diagnosis (Electrophoresis):
- ↓ HbA ($α₂β₂$)
- ↑ HbA₂ ($α₂δ₂$)
- ↑ HbF ($α₂γ₂$)

⭐ High-Yield: An elevated HbA₂ level (> 3.5%) is the key diagnostic finding for β-thalassemia minor (trait).
Diagnosis & Management - Spot & Support
- Management Strategy:
- Mild (carrier): Genetic counseling.
- Moderate/Severe (Major):
- Chronic Blood Transfusions: Maintain Hb >9-10 g/dL to support growth and suppress extramedullary hematopoiesis.
- Iron Chelation: Essential to prevent secondary hemochromatosis. Agents include Deferoxamine, Deferasirox.
- Splenectomy: Considered if hypersplenism increases transfusion requirements.
- Curative Option: Allogeneic hematopoietic stem cell transplantation.
⭐ High-Yield: In β-thalassemia minor, HbA2 levels are characteristically elevated (>3.5%) on electrophoresis, a key diagnostic differentiator.
High‑Yield Points - ⚡ Biggest Takeaways
- α-thalassemia is caused by gene deletions on chromosome 16; β-thalassemia results from point mutations on chromosome 11.
- Hallmark is microcytic anemia with a normal or ↑ RBC count and a very low MCV.
- Unlike iron deficiency, serum iron and ferritin levels are normal or elevated.
- Hb electrophoresis is key for diagnosis, showing ↑ HbA2/HbF in β-thalassemia.
- Severe forms (β-thal major, HbH disease) require lifelong blood transfusions and iron chelation therapy.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app